Nestlé Divests Peanut Allergy Brand to Stallergenes Greer
Nestlé Health Science announced on September 5 its divestment of Palforzia, a children’s peanut allergy drug, to Stallergenes Greer International AG. According to data captured in the LevinPro HC database, this transaction represents the 77th Pharmaceuticals acquisition of 2023. Palforzia became the first drug approved by the FDA for peanut allergy in children in January 2020. At the time, it was projected that the drug could reach $1.28 billion in sales by 2024. Backed by B-FLEXION, Stallergenes Greer International AG is a global biopharmaceutical company. It is based in Baar, Switzerland and specializes in the diagnosis and treatment of respiratory allergies through... Read More »
VitalPoint Technologies Acquires Herban Healing
Houston-based VitalPoint Technologies, Inc. (VPT) announced on August 31 it acquired Herban Healing, LLC. The financial terms of the transaction were not disclosed. Herban Healing is a Texas-based biopharmaceutical company focused on healthcare products centered around CBD. Co-Founders Kyle Williams and Jennifer Gillelan established Herban Healing with the goal of addressing the opioid epidemic. Founded in 2019, the company operates two locations in Cypress, Texas and one in North Spring, Texas. VitalPoint Technologies was established to conduct research, develop solutions and provide education on alternative healthcare options. VPT is a tech-enabled innovative Healthcare... Read More »
LEO Pharma Acquires Timber Pharmaceuticals
LEO Pharma A/S announced on August 21 it acquired Timber Pharmaceuticals LLC, a biopharmaceutical company focused on developing and commercializing treatments for orphan dermatologic diseases. Timber Pharmaceuticals’ lead investigational product candidate, TMB-001, is a topical reformulation of the active ingredient, isotretinoin, which is aimed at treating congenital ichthyosis, a rare skin disease with significant unmet needs and no approved prescription therapies available. Founded in 1908, LEO Pharma A/S is owned by the LEO Foundation, one of Denmark’s largest commercial foundations. LEO Pharma is a specialty pharmaceutical company focused on dermatology, and markets products in more... Read More »
Harmony Biosciences Holdings Acquires Zynerba Pharmaceuticals
On August 14, Harmony Biosciences Holdings, Inc. announced that it acquired Zynerba Pharmaceuticals, Inc. for $60 million. According to data captured in the LevinPro HC database, this transaction marks the 66th Pharmaceuticals acquisition of 2023. Zynerba Pharmaceuticals is a leader in innovative pharmaceutically produced, synthetic transdermal cannabidiol therapies for orphan neuropsychiatric disorders, including Fragile X syndrome. Zynerba’s lead asset, Zygel, is the first pharmaceutically manufactured, synthetic cannabidiol, formulated as a patent-protected permeation-enhanced gel for transdermal delivery through the skin and into the circulatory system. Harmony Biosciences... Read More »
Men’s Health Provider Acquires Colombia-Based Medical Marijuana Company
Ultimate Sports, Inc. has acquired Sannabis S.A.S., a medical marijuana company based in Colombia. Terms of the deal were not disclosed. Sannabis is a licensed cannabis company operating in Cali, Colombia. It has a line of cosmetic, medical and industrial products made from cannabis and hemp. The company is licensed to grow, manufacture and export cannabis and cannabis derivatives. Ultimate Sports is a men’s health services provider. Ultimate Sports’ Men’s Advanced RX Online Medical Clinic provides a licensed physician to diagnose and treat male health and wellness issues. Ultimate Sports named Juan Paulo Guzmán and John Campo, Sannabis co-founders, to the board of directors. Guzman... Read More »Schedule a demo
Gain access to the best healthcare and long-term care investment intelligence, data, and analysis.
